Nagehan Didem Sarı
Research Subjects
Nagehan Didem Sarı has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Gülşen Yörük
Department of Infectious Diseases, İstanbul Training and Research Hospital, İstanbul, Türkiye
7 shared publications - Ayse Batirel
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Istanbul Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
5 shared publications - Nurettin Erben
Department of Infectious Diseases and Clinical Microbiology, Eskişehir Osman Gazi University, Eskişehir, Türkiye
5 shared publications - Süheyla Kömür
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Cukurova University, Adana, Turkiye
5 shared publications - Ayse Inci
Department of Infectious Diseases and Clinical Microbiology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
4 shared publications - Behice Kurtaran
Department of Infectious Diseases and Clinical Microbiology, Acıbadem Adana Hospital, Adana 01130, Türkiye
4 shared publications
Latest Publications
- Open Access
Self-Reported History of Herpes Zoster and Awareness of Zoster Vaccination Among Healthcare Workers: A Multicenter Cross-Sectional Study
Objective: Varicella zoster virus (VZV), a member of the Herpesviridae family, is known as the causative agent of chickenpox (varicella). Following primary infection, VZV can remain latent for life and may reactivate over time to cause herpes zoster (shingles). Advanced age, immunodeficiency, and certain chronic illnesses are major risk factors for the development of herpes zoster. To prevent herpes zoster, a live zoster vaccine was licensed in 2006, followed by a recombinant zoster vaccine with higher efficacy in 2018. In Türkiye, the recombinant zoster vaccine was licensed in 2024. Raising awareness among healthcare workers is important both for their own health and the safety of vulnerable patients. This study aimed to evaluate healthcare workers’ knowledge and awareness of herpes zoster infection and zoster vaccines across the country, as well as to determine the prevalence of prior herpes zoster infection among them. Methods: After obtaining ethical approval, a nationwide multicenter survey was conducted. A questionnaire was distributed to healthcare workers via an online link. Participation was entirely voluntary. The survey collected demographic information (age, sex, profession, years of experience) and included questions on knowledge of herpes zoster, history of zoster infection, symptoms and severity (if applicable), awareness of the zoster vaccine, and vaccination attitudes. Results: A total of 5180 healthcare workers participated, of whom 3505 were female. The participants ranged in age from 18 to 79 years (mean age: 34.24 ± 11.52). Regarding professions: 47.9% were physicians, 21.3% were nurses or midwives, 0.8% were dentists or dental technicians, and 30% were from other healthcare professions. Among participants, 54.4% had ≤10 years of professional experience, 20% had comorbidities, and 10.5% were using immunosuppressive medications. It was found that 9.6% had previously had herpes zoster, 8.8% had no knowledge of the disease, 39.6% were aware of the vaccine, and 20.1% were unwilling to pay for vaccination. Multivariate binary logistic regression analysis revealed that being a physician significantly increased the likelihood of having correct knowledge by 1.961 times compared to other professions (p < 0.001, CI: 1.608–2.392). Similarly, those who had heard of herpes zoster were 3.191 times more likely to answer correctly than those who had not (p = 0.011, CI: 1.650–6.172). Male gender was significantly associated with a lower likelihood of having accurate knowledge compared to females (p = 0.001, OR = 0.720, CI: 0.594–0.874). Conclusions: This study revealed that healthcare workers’ knowledge and awareness regarding herpes zoster and its vaccines are generally insufficient. The recent licensing of the vaccine in Türkiye may explain this, but it is critical for healthcare professionals to be more informed about risk groups and vaccination indications in order to enhance the effectiveness of preventive healthcare services. Given the potential for serious complications of herpes zoster in elderly and immunocompromised individuals, the importance of vaccination should be emphasized more strongly to healthcare workers. Furthermore, the finding that 20.1% of those aware of the vaccine were deterred by its cost highlights the need to improve vaccine accessibility. Economic barriers preventing healthcare workers from being vaccinated emphasize the importance of making the vaccine widely available through public support to protect both healthcare workers and patient safety.
Open AccessSelf-Reported History of Herpes Zoster and Awareness of Zoster Vaccination Among Healthcare Workers: A Multicenter Cross-Sectional Study
Objective: Varicella zoster virus (VZV), a member of the Herpesviridae family, is known as the causative agent of chickenpox (varicella). Following primary infection, VZV can remain latent for life and may reactivate over time to cause herpes zoster (shingles). Advanced age, immunodeficiency, and certain chronic illnesses are major risk factors for the development of herpes zoster. To prevent herpes zoster, a live zoster vaccine was licensed in 2006, followed by a recombinant zoster vaccine with higher efficacy in 2018. In Türkiye, the recombinant zoster vaccine was licensed in 2024. Raising awareness among healthcare workers is important both for their own health and the safety of vulnerable patients. This study aimed to evaluate healthcare workers’ knowledge and awareness of herpes zoster infection and zoster vaccines across the country, as well as to determine the prevalence of prior herpes zoster infection among them. Methods: After obtaining ethical approval, a nationwide multicenter survey was conducted. A questionnaire was distributed to healthcare workers via an online link. Participation was entirely voluntary. The survey collected demographic information (age, sex, profession, years of experience) and included questions on knowledge of herpes zoster, history of zoster infection, symptoms and severity (if applicable), awareness of the zoster vaccine, and vaccination attitudes. Results: A total of 5180 healthcare workers participated, of whom 3505 were female. The participants ranged in age from 18 to 79 years (mean age: 34.24 ± 11.52). Regarding professions: 47.9% were physicians, 21.3% were nurses or midwives, 0.8% were dentists or dental technicians, and 30% were from other healthcare professions. Among participants, 54.4% had ≤10 years of professional experience, 20% had comorbidities, and 10.5% were using immunosuppressive medications. It was found that 9.6% had previously had herpes zoster, 8.8% had no knowledge of the disease, 39.6% were aware of the vaccine, and 20.1% were unwilling to pay for vaccination. Multivariate binary logistic regression analysis revealed that being a physician significantly increased the likelihood of having correct knowledge by 1.961 times compared to other professions (p < 0.001, CI: 1.608–2.392). Similarly, those who had heard of herpes zoster were 3.191 times more likely to answer correctly than those who had not (p = 0.011, CI: 1.650–6.172). Male gender was significantly associated with a lower likelihood of having accurate knowledge compared to females (p = 0.001, OR = 0.720, CI: 0.594–0.874). Conclusions: This study revealed that healthcare workers’ knowledge and awareness regarding herpes zoster and its vaccines are generally insufficient. The recent licensing of the vaccine in Türkiye may explain this, but it is critical for healthcare professionals to be more informed about risk groups and vaccination indications in order to enhance the effectiveness of preventive healthcare services. Given the potential for serious complications of herpes zoster in elderly and immunocompromised individuals, the importance of vaccination should be emphasized more strongly to healthcare workers. Furthermore, the finding that 20.1% of those aware of the vaccine were deterred by its cost highlights the need to improve vaccine accessibility. Economic barriers preventing healthcare workers from being vaccinated emphasize the importance of making the vaccine widely available through public support to protect both healthcare workers and patient safety.
- Open Access
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Open AccessEfficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- Open Access
- 23 January 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (2) , 537-555
Epidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from Türkiye (2004–2024)
Purpose: Mucormycosis is a rapidly progressive angioinvasive fungal infection with limited large-scale outcome data. We aimed to describe the epidemiology, clinical spectrum, treatment strategies, and predictors of outcomes in adult patients with proven mucormycosis in Türkiye. Methods: We conducted a nationwide, retrospective study of 280 adults diagnosed with proven mucormycosis between 2004 and 2024 across 27 tertiary centers. Case definitions were applied according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical characteristics, antifungal management, surgical interventions, and outcomes were systematically analyzed. Results: The median age of the cohort was 60 years, and diabetes mellitus, frequently complicated by ketoacidosis, was the most common underlying condition. Rhino-orbital-cerebral disease represented the predominant clinical form, whereas pulmonary, gastrointestinal, and disseminated presentations were less frequent but carried less favorable prognoses. Liposomal amphotericin B was the main first-line therapy, often combined with surgery, although antifungal treatment was initiated at a median of five days after symptom onset. Ninety-day mortality was 42.1% by Kaplan–Meier estimation (crude 49.3%) and reached 49.3% (crude 55.0%) at 365 days. Crude mortality was lowest in patients who did not undergo surgery; however, this association was not significant in the time-dependent Cox regression analysis, suggesting confounding by baseline severity. Poor outcomes were associated with corticosteroid exposure, prolonged neutropenia, and neurological manifestations, while a history of sinusitis appeared to be associated with improved survival. Conclusion: In this multicenter study, survival was mainly determined by host-related factors rather than the choice of antifungal agent. Corticosteroid exposure, prolonged neutropenia, and neurological involvement independently predicted poor outcomes, whereas a prior history of sinusitis was linked to improved survival, likely reflecting earlier diagnosis and intervention. These findings reinforce the need for heightened clinical awareness, rapid recognition, and prompt multidisciplinary management to improve outcomes in patients with mucormycosis.
- 23 January 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (2) , 537-555
Open AccessEpidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from Türkiye (2004–2024)
Purpose: Mucormycosis is a rapidly progressive angioinvasive fungal infection with limited large-scale outcome data. We aimed to describe the epidemiology, clinical spectrum, treatment strategies, and predictors of outcomes in adult patients with proven mucormycosis in Türkiye. Methods: We conducted a nationwide, retrospective study of 280 adults diagnosed with proven mucormycosis between 2004 and 2024 across 27 tertiary centers. Case definitions were applied according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical characteristics, antifungal management, surgical interventions, and outcomes were systematically analyzed. Results: The median age of the cohort was 60 years, and diabetes mellitus, frequently complicated by ketoacidosis, was the most common underlying condition. Rhino-orbital-cerebral disease represented the predominant clinical form, whereas pulmonary, gastrointestinal, and disseminated presentations were less frequent but carried less favorable prognoses. Liposomal amphotericin B was the main first-line therapy, often combined with surgery, although antifungal treatment was initiated at a median of five days after symptom onset. Ninety-day mortality was 42.1% by Kaplan–Meier estimation (crude 49.3%) and reached 49.3% (crude 55.0%) at 365 days. Crude mortality was lowest in patients who did not undergo surgery; however, this association was not significant in the time-dependent Cox regression analysis, suggesting confounding by baseline severity. Poor outcomes were associated with corticosteroid exposure, prolonged neutropenia, and neurological manifestations, while a history of sinusitis appeared to be associated with improved survival. Conclusion: In this multicenter study, survival was mainly determined by host-related factors rather than the choice of antifungal agent. Corticosteroid exposure, prolonged neutropenia, and neurological involvement independently predicted poor outcomes, whereas a prior history of sinusitis was linked to improved survival, likely reflecting earlier diagnosis and intervention. These findings reinforce the need for heightened clinical awareness, rapid recognition, and prompt multidisciplinary management to improve outcomes in patients with mucormycosis.
- 23 October 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (4) , 475-491
HIV Enfeksiyonu Tanı Verilerinin Üç yıllık Çok Merkezli Analizi
Türkiye'de kullanılan üç basamaklı insan immün yetmezlik virüsü [human immunodeficiency virus (HIV)] testi algoritması, Centers for Disease Control and Prevention güncel HIV testi algoritmasına uygun olarak 2019 yılında güncellenmiş ve yürürlüğe girmiştir. Bu çalışmada, HIV/edinilmiş bağışıklık yetmezliği sendromu tanısında ülkemizdeki mevcut durumun ortaya konması amacıyla çok merkezli ve multidisipliner bir yaklaşımla HIV test verileri hakkında çok merkezli veri elde edilebilmesi ve HIV tanısında yeni algoritma uygulamaları ve sahada yaşanılan problemlerin tespit edilebilmesi amaçlanmıştır. Bu amaçla 12 HIV test merkezine 57 soruluk bir anketle kullandıkları HIV test algoritmaları, uygulamada karşılaştıkları sorunlar ve çözüm önerileri sorulmuştur. 2018-2020 yılları arasındaki toplam üç yıllık dördüncü kuşak HIV enzim bağlantılı immünosorbent testi [enzyme linked immunsorbent assay (ELISA)] test sayıları, tekrarlayan reaktif test sayıları, HIV doğrulama test sonuçlarının dağılımı ve HIV nükleik asit amplifikasyon test (NAT) sayıları ile mevcut algoritmanın performansı ve merkezlerin güncel HIV durumu değerlendirilmiştir. 2018-2020 yılları arasında toplam çalışılan anti-HIV ELISA test sayıları yıllara göre sırasıyla 788261, 871299, 835498, tekrarlayan reaktivite oranları 0.48, 0.51 ve 0.70 iken; doğrulanmış HIV test oranları ise 0.24, 0.25 ve 0.21 olarak bulunmuştur. Bu dönemde Western Blot (WB) doğrulama testi kullanım oranları sırasıyla %25.77, %12.29 ve %9.86 olup kullanımının giderek azaldığı görülmektedir. Mevcut algoritmada önerilen HIV-1/2 antikor ayırt edici hızlı doğrulama testlerinin (AAEHDT) kullanım oranları sırasıyla %25.72, %38.76 ve %45.78 olarak bulunmuş olup WB'nin yerini aldığı görülmektedir. Yıllara göre çalışılan HIV-1 RNA oranları da sırasıyla %48.77, %97.98 ve %46.31 olarak bulunmuştur. Çalışmada yeni algoritmada yer alan HIV-1/2 antikor ayırt edici hızlı doğrulama testinin kullanımının giderek arttığı ve HIV tanısında daha etkin kullanıldığı, HIV-1 NAT kullanımının ise azaldığı görülmektedir. Koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] pandemisinin gölgesinde NAT olanaklarının COVID-19 polimeraz zincir reaksiyonu çalışmalarına kaydırılmasıyla ilişkilendirilen bu durum, ülkemizdeki HIV salgınındaki olası değişimler açısından daha detaylı izlem gerektirmektedir.
- 23 October 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (4) , 475-491
HIV Enfeksiyonu Tanı Verilerinin Üç yıllık Çok Merkezli Analizi
Türkiye'de kullanılan üç basamaklı insan immün yetmezlik virüsü [human immunodeficiency virus (HIV)] testi algoritması, Centers for Disease Control and Prevention güncel HIV testi algoritmasına uygun olarak 2019 yılında güncellenmiş ve yürürlüğe girmiştir. Bu çalışmada, HIV/edinilmiş bağışıklık yetmezliği sendromu tanısında ülkemizdeki mevcut durumun ortaya konması amacıyla çok merkezli ve multidisipliner bir yaklaşımla HIV test verileri hakkında çok merkezli veri elde edilebilmesi ve HIV tanısında yeni algoritma uygulamaları ve sahada yaşanılan problemlerin tespit edilebilmesi amaçlanmıştır. Bu amaçla 12 HIV test merkezine 57 soruluk bir anketle kullandıkları HIV test algoritmaları, uygulamada karşılaştıkları sorunlar ve çözüm önerileri sorulmuştur. 2018-2020 yılları arasındaki toplam üç yıllık dördüncü kuşak HIV enzim bağlantılı immünosorbent testi [enzyme linked immunsorbent assay (ELISA)] test sayıları, tekrarlayan reaktif test sayıları, HIV doğrulama test sonuçlarının dağılımı ve HIV nükleik asit amplifikasyon test (NAT) sayıları ile mevcut algoritmanın performansı ve merkezlerin güncel HIV durumu değerlendirilmiştir. 2018-2020 yılları arasında toplam çalışılan anti-HIV ELISA test sayıları yıllara göre sırasıyla 788261, 871299, 835498, tekrarlayan reaktivite oranları 0.48, 0.51 ve 0.70 iken; doğrulanmış HIV test oranları ise 0.24, 0.25 ve 0.21 olarak bulunmuştur. Bu dönemde Western Blot (WB) doğrulama testi kullanım oranları sırasıyla %25.77, %12.29 ve %9.86 olup kullanımının giderek azaldığı görülmektedir. Mevcut algoritmada önerilen HIV-1/2 antikor ayırt edici hızlı doğrulama testlerinin (AAEHDT) kullanım oranları sırasıyla %25.72, %38.76 ve %45.78 olarak bulunmuş olup WB'nin yerini aldığı görülmektedir. Yıllara göre çalışılan HIV-1 RNA oranları da sırasıyla %48.77, %97.98 ve %46.31 olarak bulunmuştur. Çalışmada yeni algoritmada yer alan HIV-1/2 antikor ayırt edici hızlı doğrulama testinin kullanımının giderek arttığı ve HIV tanısında daha etkin kullanıldığı, HIV-1 NAT kullanımının ise azaldığı görülmektedir. Koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] pandemisinin gölgesinde NAT olanaklarının COVID-19 polimeraz zincir reaksiyonu çalışmalarına kaydırılmasıyla ilişkilendirilen bu durum, ülkemizdeki HIV salgınındaki olası değişimler açısından daha detaylı izlem gerektirmektedir.
- Open Access
- 10 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (1) , 113-120
Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3
Background/Aims: This study evaluates the efficacy and safety of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) genotype 2 (GT-2) and genotype 3 (GT-3) in Türkiye. Materials and Methods: This cohort is a multicenter, retrospective, and observational study. Data from 267 GT-2 or GT-3 patients treated with a DAA were analyzed. Results: An overall sustained virological response (SVR) rate of 95.9%, with no significant difference between GTs. The SVR rates were relatively lower in patients with cirrhosis. Prior pegylated interferon and ribavirin reduced SVR rates, particularly in males and patients with cirrhosis. The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy. No significant drug interactions were observed. The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation. Conclusion: This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication. Cite this article as: Kaya SY, Kurtaran B, Çuvalcı NÖ, et al. Real-life experience of hepatitis C treatment with direct-acting antivirals in genotypes 2 and 3. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24751.
- 10 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (1) , 113-120
Open AccessReal-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3
Background/Aims: This study evaluates the efficacy and safety of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) genotype 2 (GT-2) and genotype 3 (GT-3) in Türkiye. Materials and Methods: This cohort is a multicenter, retrospective, and observational study. Data from 267 GT-2 or GT-3 patients treated with a DAA were analyzed. Results: An overall sustained virological response (SVR) rate of 95.9%, with no significant difference between GTs. The SVR rates were relatively lower in patients with cirrhosis. Prior pegylated interferon and ribavirin reduced SVR rates, particularly in males and patients with cirrhosis. The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy. No significant drug interactions were observed. The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation. Conclusion: This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication. Cite this article as: Kaya SY, Kurtaran B, Çuvalcı NÖ, et al. Real-life experience of hepatitis C treatment with direct-acting antivirals in genotypes 2 and 3. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24751.
- Open Access
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 1039-1062
Consensus paper on Candida auris by Türkiye EKMUD, THSK of Ministry of Health of the Republic of Türkiye, KLIMUD, TMC, TARD, TYBD and ID-IRI
Candida auris is an emerging fungal pathogen that has become a critical global health concern due to its high antifungal resistance and potential to cause nosocomial outbreaks. Since its initial identification in Japan in 2009, C. auris has spread rapidly, posing significant treatment challenges across various healthcare settings worldwide. The biofilm formation ability of C. auris enhances its resilience against disinfectants and antifungal agents, complicating infection control in healthcare environments. This consensus report, developed with the collaboration of several Turkish medical specialty societies, including the Turkish Society of Infectious Diseases and Clinical Microbiology Specialty (EKMUD), the Turkish Society of Anesthesiology and Reanimation (TARD), the Turkish Intensive Care Society (TYBD), the Infectious Diseases – International Research Initiative (ID-IRI), the Clinical Microbiology Specialist Society (KLIMUD), the Turkish Microbiology Society (TMC), and the Public Health Institution of Türkiye (PHIT) under the Ministry of Health, provides a comprehensive overview of C. auris and its’ management. The report focuses on the epidemiology, antifungal resistance mechanisms, recommendations for diagnostic and therapeutic challenges, infection control and prevention measures and surveillance of C. auris. This consensus report aims to establish standardized diagnostic protocols, improve national surveillance systems, and promote effective infection control measures to mitigate C. auris related health risks in Türkiye. It also offers comprehensive national recommendations and addresses the need for inter-institutional collaboration, improve public health, and strengthen the healthcare response to this pathogens.
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 1039-1062
Open AccessConsensus paper on Candida auris by Türkiye EKMUD, THSK of Ministry of Health of the Republic of Türkiye, KLIMUD, TMC, TARD, TYBD and ID-IRI
Candida auris is an emerging fungal pathogen that has become a critical global health concern due to its high antifungal resistance and potential to cause nosocomial outbreaks. Since its initial identification in Japan in 2009, C. auris has spread rapidly, posing significant treatment challenges across various healthcare settings worldwide. The biofilm formation ability of C. auris enhances its resilience against disinfectants and antifungal agents, complicating infection control in healthcare environments. This consensus report, developed with the collaboration of several Turkish medical specialty societies, including the Turkish Society of Infectious Diseases and Clinical Microbiology Specialty (EKMUD), the Turkish Society of Anesthesiology and Reanimation (TARD), the Turkish Intensive Care Society (TYBD), the Infectious Diseases – International Research Initiative (ID-IRI), the Clinical Microbiology Specialist Society (KLIMUD), the Turkish Microbiology Society (TMC), and the Public Health Institution of Türkiye (PHIT) under the Ministry of Health, provides a comprehensive overview of C. auris and its’ management. The report focuses on the epidemiology, antifungal resistance mechanisms, recommendations for diagnostic and therapeutic challenges, infection control and prevention measures and surveillance of C. auris. This consensus report aims to establish standardized diagnostic protocols, improve national surveillance systems, and promote effective infection control measures to mitigate C. auris related health risks in Türkiye. It also offers comprehensive national recommendations and addresses the need for inter-institutional collaboration, improve public health, and strengthen the healthcare response to this pathogens.
- Open Access
- 29 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (4) , 240-246
Epidemiological Characteristics of HIV/TB Co-Infected Patients and Factors Affecting Tuberculosis Treatment Success
Objective: Tuberculosis (TB) is the most important opportunistic infection and one of the leading causes of death in individuals living with human immunodeficiency virus (HIV). Treatment of HIV/TB coinfected patients is more complicated than that of individuals living with HIV only. We aimed to determine the epidemiological characteristics of HIV/TB coinfected patients and the factors affecting TB treatment success. Methods: This retrospective study was conducted between January 2006 and December 2022. Among individuals living with HIV, those aged ≥18 years and with active tuberculosis were included in the study. Sociodemographic, clinical and laboratory findings of HIV/TB coinfected patients were recorded from their files. Patients were divided into two groups according to TB treatment response. The statistical significance level was accepted as p + 3, 10 (13.5%) had negative viral load and only 12 (16.2%) had received antiretroviral treatment (ART). Of these patients, 42 (56.8%) were evaluated as pulmonary TB and 32 (43.2%) as extrapulmonary TB. TB treatment was successful in 49 (%66.2) of the patients; 15 (%20.3) died, 5 (%6.8) received insufficient treatment, 2 (%2.7) were lost to follow-up, and 3 (%4.1) were transferred to another centre. Unsuccessful TB treatment outcomes were associated with a higher mortality rate (20.3%) and increasing age (p<0.05). Conclusion: In our study, the success rate of TB treatment in HIV/TB coinfected individuals was determined as 66.2%. Our findings were lower than World Health Organization targets. The high mortality rate and the advancing age of the patients were determined to be the most critical factors affecting the success of the TB treatment. We conclude that more attention should be paid to HIV/TB coinfected patients, strategies should be developed to ensure early diagnosis, and more comprehensive and prospective studies on this subject need to be conducted in our country.
- 29 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (4) , 240-246
Open AccessEpidemiological Characteristics of HIV/TB Co-Infected Patients and Factors Affecting Tuberculosis Treatment Success
Objective: Tuberculosis (TB) is the most important opportunistic infection and one of the leading causes of death in individuals living with human immunodeficiency virus (HIV). Treatment of HIV/TB coinfected patients is more complicated than that of individuals living with HIV only. We aimed to determine the epidemiological characteristics of HIV/TB coinfected patients and the factors affecting TB treatment success. Methods: This retrospective study was conducted between January 2006 and December 2022. Among individuals living with HIV, those aged ≥18 years and with active tuberculosis were included in the study. Sociodemographic, clinical and laboratory findings of HIV/TB coinfected patients were recorded from their files. Patients were divided into two groups according to TB treatment response. The statistical significance level was accepted as p + 3, 10 (13.5%) had negative viral load and only 12 (16.2%) had received antiretroviral treatment (ART). Of these patients, 42 (56.8%) were evaluated as pulmonary TB and 32 (43.2%) as extrapulmonary TB. TB treatment was successful in 49 (%66.2) of the patients; 15 (%20.3) died, 5 (%6.8) received insufficient treatment, 2 (%2.7) were lost to follow-up, and 3 (%4.1) were transferred to another centre. Unsuccessful TB treatment outcomes were associated with a higher mortality rate (20.3%) and increasing age (p<0.05). Conclusion: In our study, the success rate of TB treatment in HIV/TB coinfected individuals was determined as 66.2%. Our findings were lower than World Health Organization targets. The high mortality rate and the advancing age of the patients were determined to be the most critical factors affecting the success of the TB treatment. We conclude that more attention should be paid to HIV/TB coinfected patients, strategies should be developed to ensure early diagnosis, and more comprehensive and prospective studies on this subject need to be conducted in our country.
- 26 December 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (4) , 470-479
Spondilodiskit Olgularının Tanı ve Tedavi Serüveni: On Bir Yıllık Tecrübe
- 26 December 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (4) , 470-479
Spondilodiskit Olgularının Tanı ve Tedavi Serüveni: On Bir Yıllık Tecrübe
- 1 December 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (4) , 363-369
Evaluation of Hepatitis C in 20 Years: A Turkish Experience
- 1 December 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (4) , 363-369
Evaluation of Hepatitis C in 20 Years: A Turkish Experience
- Open Access
- 15 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (11) , 971-978
In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis Cite this article as: Sarıgül Yıldırım F, Üser Ü, Sarı ND, et al. In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971-978
- 15 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (11) , 971-978
Open AccessIn a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis Cite this article as: Sarıgül Yıldırım F, Üser Ü, Sarı ND, et al. In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971-978